Obesity is one of the major health challenges of the 21st century, with far-reaching implications for physical, mental health, and quality of life. In a world where about 650 million people suffer from obesity, searching for effective treatments has become an urgent mission.
In recent years, a drug named Vigobi (Smagrotide), from a GLP-1 receptor agonist family, has been recognized as a significant breakthrough in obesity. Beyond its ability to help with a significant weight loss-up to 15-20% of body weight, which means an average of 15 to 30 kg for a person weighing 100 kg-Vigobi offers a unique advantage: a dramatic reduction in the “FOOD NOISE” (FOOD NOISE) and the desires for food-phenomena that make it difficult for people to maintain a healthy diet.